Skip to main content
Clinical Trials/NCT07291089
NCT07291089
Completed
Phase 4

Preoperative Pain-Risk Screening and Intervention for Intraoperative Pain in Second-Eye Cataract Surgery Based on Iris Vascular Area Density

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1 site in 1 country126 target enrollmentStarted: February 23, 2024Last updated:

Overview

Phase
Phase 4
Status
Completed
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment
126
Locations
1
Primary Endpoint
Proportion of Participants With Intraoperative Pain VAS ≥ 3 (Significant Pain)

Overview

Brief Summary

This clinical trial aims to evaluate the effectiveness of pranoprofen or prednisolone acetate eye drops for pain management in patients undergoing second-eye surgery for age-related cataracts. Researchers will compare pranoprofen or prednisolone acetate eye drops with sodium hyaluronate eye drops to determine whether pranoprofen or prednisolone acetate eye drops can relieve intraoperative pain during second-eye cataract surgery.

Participants will:

  1. Receive one drop in the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery (pranoprofen, prednisolone acetate, or sodium hyaluronate)
  2. Undergo cataract surgery and routine postoperative follow-up
  3. Within 1 hour after surgery, provide a pain visual analog scale (VAS) score under the guidance of the investigator

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
50 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Aged ≥ 50 years.
  • Definite diagnosis of age-related cataract.
  • The first-eye cataract surgery under local anesthesia has been completed at this hospital, and the second-eye cataract surgery under local anesthesia is planned with the same surgeon within 1 year of the first-eye surgery.
  • Able to cooperate with preoperative iris optical coherence tomography angiography (OCTA) examination of the operative eye.
  • On the day of the second-eye surgery, preoperative iris vascular area density (VAD) ≥ 0.2167 in the operative eye.

Exclusion Criteria

  • History of ocular trauma, ocular surgery (excluding the first-eye cataract surgery already performed), uveitis, chorioretinal disease, glaucoma;
  • Presence of significant corneal disease, marked iris abnormalities, or any active ocular surface disease, including recent conjunctivitis, keratitis, or severe dry eye.
  • Severe complications during or after the first-eye surgery (e.g., posterior capsule rupture, zonular dialysis, dislocation of the lens nucleus into the vitreous cavity, postoperative endophthalmitis, or glaucoma).
  • History of chronic pain syndromes or neuropathic pain.
  • Long-term use of opioids, other systemic analgesics, or sedative-hypnotic drugs.
  • Known autoimmune disease or ongoing immunosuppressive therapy.
  • Severe psychiatric disorders or cognitive impairment interfering with pain assessment.
  • Use of topical corticosteroid eye drops in the second eye within 1 month prior to the planned surgery.
  • Long-term use of α-adrenergic blockers or other medications associated with intraoperative floppy iris syndrome (IFIS).
  • Participation in any other clinical trial involving ophthalmic or systemic drugs within the past 6 months.

Arms & Interventions

Pranoprofen ophthalmic solution group

Experimental

Intervention: Pranoprofen eye drops (Drug)

Prednisolone acetate ophthalmic suspension group

Experimental

Intervention: Prednisolone acetate eye drops (Drug)

Sodium hyaluronate ophthalmic solution group

Placebo Comparator

Intervention: Sodium hyaluronate eye drops (Drug)

Outcomes

Primary Outcomes

Proportion of Participants With Intraoperative Pain VAS ≥ 3 (Significant Pain)

Time Frame: Within 1 hour after surgery

Intraoperative pain is assessed within 1 hour after surgery using a 0-10 visual analog scale (VAS; 0 = no pain, 10 = most severe pain). The investigator presents the unmarked side to the participant to mark perceived intraoperative pain; the investigator reads the corresponding value on the marked reverse side and records the score. The primary endpoint is the proportion of participants with VAS ≥ 3.

Secondary Outcomes

  • Intraoperative Pain VAS Score(Within 1 hour after surgery)
  • Patient-Reported Comparison of Second-Eye vs First-Eye Intraoperative Pain(Within 1 hour after surgery)

Investigators

Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Huiyi Jin

Principal Investigator, Associate Chief Physician

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Sites (1)

Loading locations...

Similar Trials